

Applicant : Klaus Cichutek et al.  
Serial No. : Unassigned  
Filed : Herewith  
Page : 2

--Summary of the Invention--

At page 3, after the 8<sup>th</sup> full paragraph (after line 30), insert

--Brief Description of the Drawings

Fig. 1 is a representation of a nucleic acid sequence of the invention, 7A5-scFv (SEQ ID NO:1), and the amino acid sequence it encodes (SEQ ID NO:6).

Fig. 2 is a representation of a nucleic acid sequence of the invention, K6-scFv (SEQ ID NO:2), and the amino acid sequence it encodes (SEQ ID NO:7).

Fig. 3 is a representation of a nucleic acid sequence of the invention, 7B2-scFv (SEQ ID NO:3), and the amino acid sequence it encodes (SEQ ID NO:8).

Fig. 4 is a representation of a nucleic acid sequence of the invention, 7E4-scFv (SEQ ID NO:4), and the amino acid sequence it encodes (SEQ ID NO:9).

Fig. 5 is a representation of a nucleic acid sequence of the invention, 6C3-scFv (SEQ ID NO:5), and the amino acid sequence it encodes (SEQ ID NO:10).

Detailed Description—

At page 9, after the last paragraph, insert:

--All references cited herein are incorporated by reference in their entirety.--

In the claims:

Amend claims 3, 4, 6, 7, 8, and 9 as follows:

3. (Amended) The cell targeting vector of claim 1, wherein the vector is T cell specific.
4. (Amended) The cell targeting vector of claim 1, wherein the vector is derived from SNV (Spleen Necrosis Virus).
6. (Amended) The cell targeting vector of claim 4, further comprising a therapeutic gene.
7. (Amended) A pharmaceutical composition containing cell targeting vectors of claim 4.